DOCTORS and a patients' charity have criticised the decision by Scotland's medicines regulator to reject the use of a drug on the NHS for people with an otherwise untreatable skin cancer.
The makers of ipilimumab claim that with a funding package in place the cost per patient of providing the drug for people with malignant melanoma is £45,000 and this on average adds between four and five months to patients' lives.
But the Scottish Medicines Consortium (SMC), responsible for approving medicines for use by NHS Scotland, yesterday rejected the treatment for such melanoma, which affects around 1200 patients in Scotland each year, saying it was not value for money.
The drug is marketed as Yervoy by drugs firm Bristol-Myers Squibb (BMS) and is currently available south of the Border under the Cancer Drugs Fund while the SMC's English equivalent Nice considers its position on providing the drug.
Leigh Smith of Melanoma Action and Support Scotland said: "It leaves many Scottish patients suffering from this devastating disease with no option but to consider moving to England where funding for the treatment can potentially be accessed."
Although the drug can theoretically be accessed on a case by case basis in Scotland since it gained European approval in 2011, BMS believes no such applications had been granted.
The SMC said: "SMC did not accept ipilimumab because weaknesses in the economic case submitted by the company and the justification of costs in relation to benefits meant the medicine was not considered to offer value for money."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article